These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 37282600)
21. Multicenter surveillance of Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR; Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656 [TBL] [Abstract][Full Text] [Related]
22. Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms. Koenig C; Kuti JL Pharmacotherapy; 2024 Aug; 44(8):658-674. PubMed ID: 38949413 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Aktaş Z; Kayacan C; Oncul O Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508 [TBL] [Abstract][Full Text] [Related]
24. Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii. Vázquez-Ucha JC; Maneiro M; Martínez-Guitián M; Buynak J; Bethel CR; Bonomo RA; Bou G; Poza M; González-Bello C; Beceiro A Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807908 [TBL] [Abstract][Full Text] [Related]
25. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
26. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732 [TBL] [Abstract][Full Text] [Related]
27. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres. Khan Z; Iregui A; Landman D; Quale J J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277 [TBL] [Abstract][Full Text] [Related]
28. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020. Lee YL; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR Int J Antimicrob Agents; 2021 Sep; 58(3):106377. PubMed ID: 34166777 [TBL] [Abstract][Full Text] [Related]
29. Molecular docking, dynamics and free energy analyses of Ramachandran B; Jeyakanthan J; Lopes BS J Med Microbiol; 2020 Aug; 69(8):1062-1078. PubMed ID: 32773005 [No Abstract] [Full Text] [Related]
30. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. Le Terrier C; Nordmann P; Sadek M; Poirel L J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067 [TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii. Wang YC; Huang SW; Chiang MH; Lee IM; Kuo SC; Yang YS; Chiu CH; Su YS; Chen TL; Wang FD; Lee YT J Antimicrob Chemother; 2021 Jan; 76(2):451-459. PubMed ID: 33057603 [TBL] [Abstract][Full Text] [Related]